Copyright
©The Author(s) 2016.
World J Gastroenterol. Jan 28, 2016; 22(4): 1711-1720
Published online Jan 28, 2016. doi: 10.3748/wjg.v22.i4.1711
Published online Jan 28, 2016. doi: 10.3748/wjg.v22.i4.1711
Table 1 Cut-off values of the first indirect markers of fibrosis in the diagnosis of significant fibrosis and cirrhosis1
| Cut-off values of some indirect markers | ||||
| Markers | Algorithm | Aetiology | ≥Significant fibrosis | Extensive fibrosis or cirrhosis |
| APRI | HCV | > 1.5 | ≥ 2 | |
| Wai et al[20], 2003 | AST (UI/L)/platelet count (109/L) × 100 | |||
| FORNS INDEX | HCV | > 6.9 | ||
| Forns et al[21], 2002 | 7.811-3.131 × ln (platelet count) + 0.781 × ln (GGT) + 3.467 × ln (age [years]) - 0.014 × ln (cholesterol) | |||
| FIBROTEST®Imbert-Bismut et al[22], 2001 | Formula combining α-2-macroglobulin, γGT, apolipoprotein A1, haptoglobin, total bilirubin, age and gender | HCV | ≥ 0.6 | |
| LOK Lok et al[23], 2005 | Log odds = -5.56-0.0089 × platelet count (× 103/mm3) + 1.26 × AST/ALT ratio + 5.27 × INR | HCV | ≥ 0.5 | |
| FIBROINDEX | CLD | ≥ 2.25 | ||
| Koda et al[24], 2007 | 1.738-0.064 [platelet counts (104/mm3)] + 0.005 × AST (UI/L) + 0.463 [gamma-globulin (g/dL)] | |||
| FIB-4 | CLD | > 3.25 | ||
| Vallet-Pichard et al[25], 2007 | Age (yr) × AST (UI/L)/[platelet count (109/L)] × [ALT (UI/L)]1/2 | |||
Table 2 Cut-off values of stiffness in relation to METAVIR score based on the prevalence of disease in studies conducted before 2009
| Cut off values of stiffness | |||||
| Authors | Aetiology | ≥F2 | ≥F3 | ≥F4 | PPV/NPV (%) |
| Castera et al[50] | HCV | 7.1 | 95/48 | ||
| 9.5 | 87/81 | ||||
| 12.5 | 77/95 | ||||
| Ziol et al[51] | |||||
| HCV | 8.8 | 88/56 | |||
| 9.6 | 71/93 | ||||
| 14.6 | 78/97 | ||||
| Carrion et al[52] | |||||
| HCV post-LT | 8.5 | 79/92 | |||
| 12.5 | 50/100 | ||||
| Foucher et al[53] | |||||
| CLD | 7.2 | 90/52 | |||
| 12.5 | 90/80 | ||||
| 17.6 | 91/92 | ||||
| Gomez-Dominguez et al[54] | |||||
| CLD | 4.0 | 88/50 | |||
| 11.0 | 78/76 | ||||
| 16.0 | 80/98 | ||||
| Kim et al[55] | |||||
| CLD | 7.3 | 96/50 | |||
| 8.8 | 78/95 | ||||
| 15.0 | 33/97 | ||||
| Arena et al[56] | |||||
| HCV | 7.8 | 83/79 | |||
| 10.8 | 89/95 | ||||
| 14.8 | 73/98 | ||||
- Citation: Stasi C, Milani S. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. World J Gastroenterol 2016; 22(4): 1711-1720
- URL: https://www.wjgnet.com/1007-9327/full/v22/i4/1711.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i4.1711
